Overview
- Two major analyses published in late August 2026 reported that recipients of the recombinant shingles vaccine Shingrix had lower rates of dementia diagnoses and lower cardiovascular disease burden compared with comparison groups.
- A Brown University study using Medicare claims and electronic health records with a target‑trial emulation found a 24% lower dementia diagnosis rate over four years among nursing‑facility residents who received Shingrix versus unvaccinated peers.
- An Oxford‑led analysis that exploited the rapid U.S. switch from the live Zostavax vaccine to Shingrix used a natural‑experiment design on about 72,000 TriNetX records and found 9% more time free of cardiovascular disease over seven years and roughly 10–12% lower risk of coronary heart disease and heart failure.
- Authors and outside experts stress these results are associative only; both studies used stronger observational methods to reduce bias but cannot rule out remaining confounding, and Brown investigators disclosed funding from GSK.
- Randomized trials, including Denmark’s large DAN ZOSTER study, are underway with initial results expected in 2027, and researchers say lab work on the AS01 adjuvant and 'trained immunity' is needed to test biological plausibility and guide policy if effects prove causal.